FINWIRES · TerminalLIVE
FINWIRES

$TAK

4 stories mentioning TAKUpdated just now

Every FINWIRES story that references TAK, newest first.

Asia Markets

Asian Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

Asian equities traded in the US as American depositary receipts fell Tuesday morning, tumbling 3.1% to 2,816.27 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by mobile app developer Cheetah Mobile (CMCM) and pharmaceutical company Takeda Pharmaceutical (TAK), which rose 2% each. They were followed by travel company Tuniu (TOUR), which was up 0.1%.The decliners from North Asia were led by fintech firm Jiayin Group (JFIN) and semiconductor company ASE Technology (ASX), which fell 29.9% and 7.6% respectively. They were followed by video display maker LG Display (LPL) and semiconductor company Silicon Motion Technology (SIMO), which shed 6.9% and 6.4% respectively.From South Asia, the gainers were led by IT firm Wipro (WIT) and telecommunications operator Telekomunikasi Indonesia (TLK), which increased 3.1% and 1.5% respectively. They were followed by IT firm Infosys (INFY) and pharmaceutical company Dr. Reddy's Laboratories (RDY), which advanced 1% each.The decliners from South Asia were lenders ICICI Bank (IBN) and HDFC Bank (HDB), which were down 1% and 0.5% respectively.

$ASX$CAN$CMCM$IBN$INFY$JFIN$LPL$RDY$SIFY$SIMO$TAK$TDTH$TLK$TOUR$WIT
Asia Markets

Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading

Asian equities traded in the US as American depositary receipts opened the trading week sharply higher Monday morning, rising 1.19% to 2,889.22 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by electric vehicle maker NIO (NIO) and semiconductor company Himax Technologies (HIMX), which climbed 6.8% and 6.3% respectively. They were followed by fintech firm Qfin (QFIN) and entertainment streaming service Bilibili (BILI), which advanced 5.8% and 5.1% respectively.The decliners from North Asia were led by real estate management and digital security company Eason Technology (DXF) and mobile app developer Cheetah Mobile (CMCM), which shed 20% and 6.4% respectively. They were followed by solar panel maker JinkoSolar (JKS) and pharmaceutical company Takeda Pharmaceutical (TAK), which dropped 5.4% and 4.2% respectively.From South Asia, the gainers were led by tech conglomerate Sea (SE) and IT firm Infosys (INFY), which rose 5.3% and 2.5% respectively. They were followed by telecommunications operators Telekomunikasi Indonesia (TLK) and PLDT (PHI), which were up 0.4% and 0.1% respectively.The decliners from South Asia were led by computer hardware maker Canaan (CAN) and IT firm Sify Technologies (SIFY), which fell 3.8% and 2.9% respectively. They were followed by pharmaceutical company Dr. Reddy's Laboratories (RDY) and lender ICICI Bank (IBN), which were down 2.1% and 1.3% respectively.

$BILI$CAN$CMCM$DXF$HIMX$IBN$INFY$JKS$NIO$PHI$QFIN$RDY$SE$SIFY$TAK$TLK
Wire

Jury Orders Takeda to Pay Hundreds of Millions in Antitrust Case, Bloomberg Reports

Jury Orders Takeda to Pay Hundreds of Millions in Antitrust Case, Bloomberg Reports

$TAK
Wire

Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical

Protagonist Therapeutics (PTGX) exercised its right to opt out of the 50/50 US profit and loss sharing arrangement under its global license and collaboration agreement with Takeda Pharmaceutical (TAK) for rusfertide, Protagonist Therapeutics said Tuesday.As a result, Protagonist Therapeutics will be eligible to receive up to $400 million in opt-out payments.The company will also be entitled to a $75 million milestone payment upon rusfertide's approval in the US and up to $975 million in other milestone payments and tiered royalties on net sales, according to the statement.Takeda Pharmaceutical now holds exclusive development and commercialization rights to rusfertide in the US.Rusfertide is under FDA Priority Review in the US for the treatment of adult patients with polycythemia vera, Protagonist Therapeutics said.Price: $99.31, Change: $+0.84, Percent Change: +0.85%

$PTGX$TAK

Track with the FINWIRES app suite